Publicaciones en colaboración con investigadores/as de Hadassah Medical Center (29)

2023

  1. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  2. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

  2. Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: Results from an international snapshot audit

    Diseases of the Colon and Rectum

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

2016

  1. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: Efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

    Bone Marrow Transplantation, Vol. 51, Núm. 3, pp. 365-371

  2. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

    Blood, Vol. 128, Núm. 9, pp. 1174-1180

  3. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  5. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  6. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

    Drugs, Vol. 76, Núm. 8, pp. 853-867

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

  2. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT

    Bone marrow transplantation, Vol. 49, Núm. 9, pp. 1170-1175

  3. International Myeloma Working Group recommendations for global myeloma care

    Leukemia, Vol. 28, Núm. 5, pp. 981-992

  4. Mutant cohesin in premature ovarian failure

    New England Journal of Medicine, Vol. 370, Núm. 10, pp. 943-949